Three biotech stocks to buy for healthy long-term returns

Professional investor Marek Poszepczynki of the International Biotechnology Trust picks three biotech stocks with strong balance sheets that look well placed to weather the crisis.

Healthcare is typically immune to a global economic downturn as demand for medications remains relatively consistent. The Covid-19 pandemic, moreover, could give the biotechnology sector a long-term fillip. Biotech will be central to developing both treatments and vaccines to control the disease. The stocks that help society navigate the challenge posed by the virus are likely to perform well; the same will apply to those that manage to maintain their existing drug sales. 

Some companies will, however, see their business models come under threat. In particular, contract-research organisations will struggle because many clinical trials will be paused or abandoned. Those with limited cash reserves will also be hit hard as it will be difficult to raise more money. 

Firms specialising in inessential drugs for the elderly will see their sales falter as treatment for conditions that are not urgent, such as glaucoma and osteoporosis, can be postponed and the elderly will avoid going out to the pharmacy or GP for treatments. Here are three stocks with strong balance sheets that look well placed to weather the crisis.

A defence against muscular dystrophy 

Rare-disease specialist PTC Therapeutics (Nasdaq: PTCT) treats Duchenne muscular dystrophy, which causes a progressive loss of skeletal and heart muscle. PTC has two drugs on the market: Translarna, which tackles the condition when it is caused by a specific genetic defect, and Emflaza, which can be used by all sufferers of the disease.

As Duchenne is a severe disease, patients cannot miss their treatments. This will help protect PTC sales during the Covid-19 outbreak. PTC has also developed an oral version of a spinal muscular atrophy drug known as Risdiplam. The current formulation is administered intravenously. An oral option will mean patients needn’t make regular visits to the hospital.

Danish oncology specialist Genmab (Copenhagen: GMAB) makes monoclonal antibodies (molecules that bolster or imitate the immune system’s attack on cancer cells) to target specific types of cancer. It has two drugs approved for use: Daratumumab and Ofatumumab. The first treats multiple myeloma (a cancer that forms in white blood cells) while the second treats relapsing multiple sclerosis. 

The company’s pipeline is also interesting. It is engaged in an antibody arms race, aiming to boost the ability of antibodies to kill cancer cells. It is developing several different types. For example, one will be able to carry cytotoxic agents to deliver chemotherapy directly to specific cancer cells. Another will be able to bind to a target before connecting it with a white blood cell to help kill the cancer cell. And a third will be more potent than naturally occurring antibodies to make it more effective.

Cornering the Parkinson’s market

Nuplazid, from Acadia Pharmaceuticals (Nasdaq: ACAD), is used to treat the hallucinations and delusions associated with Parkinson’s disease. This is the only drug available to treat this condition and there is no competition on the horizon.

The same drug recently completed late-stage clinical trials for the treatment of dementia-related psychosis. As there are many more people suffering from dementia than from Parkinson’s, should the drug receive approval it is likely to generate much higher sales in the future.

Recommended

Buy into the “contrarian” appeal of US growth stocks
Investment trusts

Buy into the “contrarian” appeal of US growth stocks

Investors should ignore the shift towards value stocks, says Max King, and stick with fast-growing American tech stocks. Here are two of the best inve…
26 Jan 2021
Three clean energy stocks for your portfolio
Share tips

Three clean energy stocks for your portfolio

Professional investor Christian Roessing of the Pictet Clean Energy Fund highlights of his three favourite stocks at the forefront of the clean energy…
25 Jan 2021
Eternal growth: how to invest in the future of the drinks industry
Share tips

Eternal growth: how to invest in the future of the drinks industry

Humans have been dabbling in tasty beverages for millennia. Jonathan Compton assesses the key trends in the sector and recommends seven hard- and soft…
22 Jan 2021
Share tips of the week
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
22 Jan 2021

Most Popular

The FTSE 100 is set for a makeover with an influx of new tech stocks
UK stockmarkets

The FTSE 100 is set for a makeover with an influx of new tech stocks

The FTSE 100 – the dullest index in the world – is about to reinvent itself as a host of new firms list on the market. The change is long overdue, say…
24 Jan 2021
Why we won’t see a house-price crash in 2021
House prices

Why we won’t see a house-price crash in 2021

Lockdown sent house prices berserk as cooped up home-workers fled for bigger properties in the country. And while they won’t rise quite as much this y…
18 Jan 2021
Think Tesla is a bubble? This might be the best way to bet on it bursting
Oil

Think Tesla is a bubble? This might be the best way to bet on it bursting

The huge rise in Tesla’s share price means that, by market value, it’s now the sixth-largest company in the US and and the world’s biggest car-maker. …
25 Jan 2021